Announcements
Sidley Represents Fifth Wall in Investment in Solarcycle’s Series A Financing
March 21, 2023
Sidley represented Fifth Wall as a lead investor in Solarcycle, Inc.’s Series A financing round. Solarcycle is a developer of a technology platform for scaling advanced recycling of solar systems in an effort to create a more sustainable solar industry supply chain. Other investors in the Series A round included HG Ventures, Prologis Ventures, Urban Innovation Fund, and Closed Loop Partners. In connection with the Series A financing, Fifth Wall also provided infrastructure financing for Solarcycle’s first-of-a-kind Odessa, Texas factory as part of a hybridized financing structure tailored to Solarcycle’s hardware-intensive business. The deal was featured in a recent Forbes article titled “Solarcycle Plans To Recycle 1 Million Panels A Year With Help From $30 Million In Financing.”
The Sidley team was led by corporate partners Andrew Harper and Tim Chandler, and included Jake Funk and Yasmeen Sayyah (Emerging Companies and Venture Capital); Cedric Seley (Energy and Infrastructure); Rachelle Soderstrom and Ida Ebeid (Technology and Life Sciences Transactions); and Maureen Crough (Environmental).
The Sidley team was led by corporate partners Andrew Harper and Tim Chandler, and included Jake Funk and Yasmeen Sayyah (Emerging Companies and Venture Capital); Cedric Seley (Energy and Infrastructure); Rachelle Soderstrom and Ida Ebeid (Technology and Life Sciences Transactions); and Maureen Crough (Environmental).
Contacts

Capabilities
Suggested News & Insights
Korea Night @ JPM 2026Wednesday, January 14, 2026Sidley and Innovation Endeavors Happy Hour Reception @ JPM 2026Tuesday, January 13, 2026Recharge & Recaffeinate with Sidley @ JPMMonday, January 12, 2026 – Tuesday, January 13, 2026Sidley Represents BioRender in Investment Valuing Company at $900 MillionJanuary 2, 2026Sidley Represents Armis in Its US$7.75 Billion Sale to ServiceNowDecember 23, 2025Sidley Represents Changchun GeneScience (GenSci) Pharmaceuticals in Its Strategic Licensing Agreement With Yarrow Bioscience for First-in-Class Autoimmune Thyroid Disease TherapyDecember 18, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory


